Exelixis, Inc.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients…

Biotechnology

US, Alameda [HQ]

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about Exelixis, Inc.'s gradings, price targets and earnings estimates. None

Earnings
Grading & Price

Reported

Past Estimate Consensus

Future Estimate Consensus

EPS Revenue EBITDA EBIT SGA

All monetary values are presented in USD ($). E stands for Estimate.

Download

FY	EPS		Revenue [mil.]		Profit [mil.]		EBITDA [mil.]		EBIT [mil.]		Expenses · SGA [mil.]
		E		E		E		E		E		E
2014	-1.3300	-1.470	31	43	-244	-274	-198	-222	-199	-229	50	12
2015	-1.3800	-0.846	25	34	-268	-177	-212	-124	-216	-126	50	9
2016	-0.8100	-0.433	37	180	-169	322	-119	33	-120	31	57	50
2017	-0.2800	0.490	191	452	-70	255	-22	293	-27	280	116	332
2018	0.5200	1.286	452	812	154	1,244	167	606	165	570	159	267
2019	2.3200	0.965	853	968	690	232	452	291	438	266	206	172
2020	1.0600	0.315	967	988	321	-224	369	-236	369	-329	228	275
2021	0.3600	0.478	987	1,338	111	584	110	775	110	731	293	838
2022	0.7300	0.564	1,434	1,603	231	677	286	901	286	858	401	810
2023	0.5700	0.617	1,611	1,831	182	207	201	999	201	951	459	900
2024	0.6500	1.669	1,830	2,152	207	536	196	398	170	371	542	600
2025	-	1.641	-	2,188	-	497	-	405	-	377	-	610
2026	-	2.F12X/td>	-	2.F12X/td>	-	2.F12X/td>	-	2.F121/td>	-	2.F121	-	2.F121
2027	-	1.F13X/td>	-	1.F13X/td>	-	1.F13X/td>	-	1.F131/td>	-	1.F131	-	1.F131
2028	-	0.F14X/td>	-	0.F14X/td>	-	0.F14X/td>	-	0.F141/td>	-	0.F141	-	0.F141